Chemomab Therapeutics (CMMB) Short-term Investments (2018 - 2025)

Chemomab Therapeutics' Short-term Investments history runs 7 years deep, the most recent figure standing at $2.8 million for Q4 2025.

• Quarterly Short-term Investments rose 3586.84% year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (up 3586.84% YoY) and the FY2025 annual result came in at $2.8 million, up 3586.84% from the prior year.
• Short-term Investments was $2.8 million for Q4 2025 at Chemomab Therapeutics, down from $3.1 million in the prior quarter.
• Across five years, Short-term Investments topped out at $43.6 million in Q1 2022 and bottomed at $23000.0 in Q1 2021.
• A 5-year average of $14.7 million and a median of $11.9 million in 2023 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments surged 189373.91% — and 2023, when it tumbled 99.71%.
• Chemomab Therapeutics' Short-term Investments stood at $26.5 million in 2021, then declined by 0.57% to $26.4 million in 2022, then tumbled by 99.71% to $76000.0 in 2023, then changed by 0.0% to $76000.0 in 2024, then jumped by 3586.84% to $2.8 million in 2025.
• Business Quant data shows CMMB's Short-term Investments at $2.8 million in Q4 2025, $3.1 million in Q3 2025, and $3.9 million in Q2 2025.